UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on Vertex Pharmaceuticals on 661 Data

In a report published Friday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Vertex Pharmaceuticals VRTX, and raised the price target from $75.00 to $100.00. In the report, Karnauskas noted, “661 data released today beat our positive expectations. We now model c100% success in F508del homozygous (prev. 75%) and 100% success in other Kalydeco mutations (prev. 50%), and increase market size oppy for other mutations. We also see oppy's for upside leading to VRTX FVs of $100-$150/sh. We are increasing our TP to $100 for the reasons above and reiterate our Buy rating.” Vertex Pharmaceuticals closed on Thursday at $52.87.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!